Table 1. Some Examples of Co-encapsulation of Anticancer Agents in Liposomesa.
| co-encapsulated anticancer agents | composition of liposome | size (nm) | surface properties | target tissue | status | ref |
|---|---|---|---|---|---|---|
| DOX, MLP | HSPhC, mPEG2000-DSPhE, cholesterol, MLP conjugate | 110–130 | PEG2000ylated | breast cancer | in vitro, in vivo | (115) |
| DOX, RAN-IP | DPPG, DOPE, cholesterol | 139 ± 21 | unconjugated | breast cancer | in vitro, in vivo | (116) |
| cisplatin, mifepristone | HSPhC, m-PEG2000-DSPhE, cholesterol | 109 ± 5.4 | PEG2000ylated | cervical cancer | in vitro, in vivo | (117) |
| DOX, CUR | cholesterol, egg lecithin | 100–140 | Tuftsin-conjugated | cervical cancer | in vitro, in vivo | (118) |
| cisplatin, CUR | DPPC | 100 | unconjugated | breast cancer | in vitro | (119) |
| DOX, itraconazole | soy PhC, cholesterol | 133 | pluronic P123-coated | breast cancer | in vitro, in vivo | (120) |
| DOX, MiR-101 (tumor suppressor micro-RNA) | DOTAP, mPEG2000-DSPhE, PEG-bisamine | 160 | unconjugated | hepatocellular carcinoma | in vitro, in vivo | (121) |
| PTX, resveratrol | PhC, mPEG2000-DSPhE | 50 | PEG2000ylated | breast cancer | in vitro, in vivo | (122) |
| DOX, Bmi1 siRNA | DOTAP, mPEG2000-DSPhE, PEG-bisamine | 130 | folate-conjugated | breast cancer | in vitro, in vivo | (123) |
| DOX, SATB1 shRNA | cholesterol, DPPC, DC-Chol (thermosensitive) | 238.16 ± 20.6 | unconjugated | gastric cancer | in vitro, in vivo | (124) |
| DOX, irinotecan | DSPC, cholesterol | 100 | unconjugated | ovarian cancer | in vitro, in vivo | (125) |
Abbreviations: Ald, alendronate; CUR, curcumin; DC-Chol, 3β-[N-(N′,N′-dimethylaminoethane)carbamoyl]cholesterol; DOX, doxorubicin; DOPC, 1,2-dioleoyl-sn-glycero-3-phosphocholine; DOPE, 1,2-dioleoyl-sn-glycerol-3-phosphoethanolamine; DOPG, 1,2-dioleoyl-sn-glycero-3-phospho-(19-rac-glycerol); DOTAP, 1,2-dioleoyl-3-trimethylammonium propane; DPPC, 1,2-distearoyl-sn-glycero-3-phosphocholine; DPPG, 1,2-dipalmitoyl-sn-glycerol-3-phosphate-rac-(1-glycerol); DSPC, distearoyl-sn-glycero-3-phosphocholine; HSPhC, hydrogenated soybean phosphatidylcholine; mPEG2000-DSPhE, methoxypolyethylene glycol2000-distearoylphosphatidylethanolamine; MLP, mitomycin-C lipidic prodrug; MPB-PE, maleimide-headgroup lipid 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine; PEG, polyethylene glycol; PhC, phosphatidylcholine; PTX, paclitaxel; RAN-IP, Ran-RCC1 inhibitory peptide; shRNA, small hairpin RNA; siRNA, small interfering RNA; TRAIL, tumor necrosis factor-related apoptosis-inducing ligand.